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Squamous cell carcinoma (SCC) of the oral cavity and pharynx represents the sixth most common form of malignancy worldwide.
A signiﬁcant proportion of these cases are related to human papillomavirus (HPV) infection. In general, HPV-associated SCC
is more commonly nonkeratinizing and poorly diﬀerentiated, whereas non-HPV-associated SCC is typically keratinizing and
moderately diﬀerentiated. Nevertheless, signiﬁcant overlap in morphology is seen between these two forms of SCC. The purpose
of this paper is to highlight the utility of ancillary studies in the establishment of HPV status of oropharyngeal SCC, including p16
immunohistochemistry, high-risk HPV in situ hybridization, polymerase chain reaction, and newer HPV detection modalities.
1.Introduction
Malignancy of the oral cavity and pharynx constitutes the
sixth most common form of malignancy worldwide [1]. In
the US, approximately 36,540 cases and 7880 deaths occur
per annum [2]. Greater than 90% of these malignancies
are squamous cell carcinomas (SCC) [1]. Alcohol and both
smoked and smokeless tobacco use are associated with
increased risk of developing malignancy of the oral cavity
and pharynx [3]. Studies have found a synergism between
heavy smoking and heavy alcohol use, with a reported 30-
fold increase in risk. As rates of tobacco use have declined, so
have rates of oral cavity carcinoma [3].
More recently, human papilloma virus (HPV) infection
has been implicated as a major etiologic agent for SCC devel-
opment [3–12]. HPV consists of a family of encapsulated
DNA virus containing over 100 genotypes [4]. High-risk
genotypes, most commonly types 16 and 18, are associated
with increased risk of squamous cell carcinoma in a number
of locations, including cervix, vulva, anus, and oropharynx
[4–8]. In contrast to the declining rates of tobacco and
alcohol-associated oral cavity carcinomas, the incidence SCC
of the oropharynx is increasing, in particular in the base
of tongue and tonsils [3, 6–9]. This increased incidence
is thought to reﬂect an increase in HPV-associated SCC.
Patients with HPV-associated SCC tend to be younger, more
frequently white, and more frequently male compared to
those with non-HPV associated SCC [3]. As with cervical
SCC, oropharyngeal SCC appears to be associated with
sexually transmitted HPV, as high-risk sexual behaviors,
including a high lifetime number of sexual partners and
younger age at ﬁrst intercourse, increase the risk [3, 10].
Evidence suggests that there is a causal association
between HPV infection and SCC of the oropharynx, with
molecular characteristics that distinguish it from non-
HPV-related SCC, including alterations of p16 and c-myc
expression [13–15]. The protein p16, a cyclin-dependent
kinase inhibitor, is frequently utilized as a surrogate marker
of HPV infection. Increased nuclear expression of p16 is seen
with downregulation of its regulator, Rb protein, as occurs
in functional inactivation of Rb by HPV E7 protein [3–
5, 16]. Reﬂecting the diﬀerences in pathogenesis, histologic2 Pathology Research International
distinctions between HPV and non-HPV-associated SCC are
often appreciable. Despite having a better prognosis, HPV
associated lesions tend to be nonkeratinizing, poorly diﬀer-
entiated lesions (Figure 1(a)), whereas non-HPV-associated
lesions are generally moderately diﬀerentiated and kera-
tinizing (Figure 2(a))[ 3, 4, 13, 17]. Nonetheless, signiﬁcant
overlap is seen, and both HPV and non-HPV associated
tumors frequently demonstrate intermediate features, such
as nonkeratinizing tumors with areas of obvious squamous
diﬀerentiation [13].
Distinction between HPV- and non-HPV-related SCC
is important in relation to clinical outcome. A study by
Ang et al. found three-year survival rate of 82.4% for HPV
positive tumors versus 57.1% for HPV negative tumors [18].
A number of additional studies have demonstrated similar
outcomes [8, 11, 13, 19–22]. The eﬀect appears unrelated
to the particular treatment regimen, as the prognosis has
been better for patients treated with radiotherapy [11, 19],
concomitant chemotherapy and radiotherapy [11, 18], and
surgery alone [20, 21]. Further, the favorable outcome of
HPV-associated SCC calls into question the necessity of
aggressive postoperative treatment in these cases [22]. In
the future, it is possible that treatment strategies may target
speciﬁc molecular pathways that diﬀer between HPV and
non-HPV-associatedSCC,furtherincreasingtheimportance
of this distinction.
Despite the importance of establishing the HPV status of
SCC, no consensus has been reached on the optimal way to
identify HPV-associated SCC [11]. The focus of this paper is
the use of ancillary studies in the distinction between HPV
positive and negative SCC, including immunohistochemical
(IHC) staining for p16, HPV polymerase chain reaction
(PCR) testing, and HPV in situ hybridization (ISH) analysis,
and newer techniques that are currently under investigation.
2. Immunohistochemical Stainingfor p16
IHC staining for p16 is frequently used as a surrogate marker
of HPV infection. It has the advantage of being easy to per-
form on formalin-ﬁxed, paraﬃn-embedded (FFPE) tissue,
and monoclonal antibodies against p16 are commercially
available. HPV protein E7 binds to Rb, a negative regulator
of p16 expression. Thus, HPV infection leads to increased
nuclear p16 expression. As a result, IHC staining for p16 has
asensitivityapproaching100%fordetectingHPV-associated
SCC (Figures 1(b) and 2(b))[ 13, 15].
However, p16 is overexpressed in a subset of tumors
apparently lacking evidence for the presence of HPV DNA
[4, 13, 22, 23]. Of note, Chernock et al. found that among
cases of nonkeratinizing, poorly diﬀerentiated SCC of the
oropharynx, p16 positivity by IHC staining was present in
100% of cases compared to just 69% positivity for HPV by
in situ hybridization [13]. Among these p16 positive tumors,
nodiﬀerenceinoverallordisease-speciﬁcsurvivalwasfound
between those that were HPV positive and HPV negative
[13]. Similarly, Lewis et al. found in a series of 239 cases
of oropharyngeal SCC that 187 were positive for p16 by
immunohistochemical stain [24]. Among these 187 cases, 26
(13.9%) were negative for HPV by both ISH and PCR (using
SPF10-INNO primers). In addition, there was no diﬀerence
in outcome between the p16 positive, HPV positive tumors
and the p16 positive, HPV undetectable tumors [24]. In
contrast; however, a recent study by Thavaraj et al. using a
diﬀerent set of PCR primers (GP5+/GP6+) from those in the
Lewis study found that only 2 out of 142 (1.4%) p16 positive
tonsillar SCC were negative for HPV by both PCR and ISH
[25].
It is possible, then, that there is a subset of non-HPV-
associated tumors with histologic phenotype, molecular
characteristics, and prognosis similar to HPV-associated
SCC. The percentage of these p16 positive, HPV negative
tumors varies signiﬁcantly between the Lewis and Thavaraj
studies. Whether this represents diﬀerences in sensitivities of
the HPV tests used or true diﬀerences in HPV prevalence in
diﬀerent populations is not deﬁnitely clear.
In any event, p16 positivity is a sensitive marker for
nonkeratinizing, poorly diﬀerentiated yet prognostically
favorable SCCs. While p16 may not be a speciﬁc marker of
HPV infection, it can provide important prognostic infor-
mation, and future therapies aimed at targeting this pathway
of HPV tumorigenesis may well be eﬀective in treating p16
positive, HPV negative SCC.
3. High Risk HPVIn SituHybridization
ISH testing for HPV has the beneﬁt of being the only
molecular method allowing for direct identiﬁcation of HPV
in topographical relation to the pathologic lesion in tissue
(Figures 1(c) and 2(c))[ 26]. Unlike other direct detection
methods for HPV that are performed in solutions or on solid
supports, ISH occurs in the nuclei of infected cells by way of
chromogenorﬂuorescentlabeledcomplimentarynucleiacid
probes against either DNA or mRNA [4, 26, 27]. Dot-like or
punctuate positivity on microscopic examination indicates
integration of the viral genome into the host cell genome,
whereas diﬀuse staining indicates the presence of episomal
DNA [4, 26–28].
Numerous technically validated HPV ISH assays are
commercially available, most containing a cocktail of probes
targeting multiple types of HPV. Though probes for indi-
vidual types can be used if subtyping is clinically relevant,
HPV subtype 16 is by far the most commonly found in
oropharyngealSCC[5,7,10,26].Thecommerciallyavailable
tests include INFORM HPV, Zytofast HPV probe, HPV
OncoTect Test Kit, and GenPoint HPV Biotinylated DNA
Probe [26]. These tests have demonstrated similar speciﬁcity
in HPV detection of cervical specimens [26], but to our
knowledge, comparisons of the commercially available tests
in HPV detection of oropharyngeal lesions have not been
performed.
The most common technical diﬃculties experienced
with ISH are background and an absence of signal [27].
Background, deﬁned as nonspeciﬁc binding of a probe to
nontarget molecules, can be managed by decreasing the con-
centration of the probe or optimizing the posthybridization
wash [26]. Absence of signal can be related to insuﬃcientPathology Research International 3
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Figure 1: Poorly-diﬀerentiated squamous cell carcinoma lacking clear evidence of squamous diﬀerentiation (hematoxylin and eosin) (a). In
the oropharynx, these are typically HPV-associated neoplasms. Immunohistochemical stain demonstrates diﬀuse nuclear and cytoplasmic
staining for p16 (b), while in situ hybridization highlights the presence of HPV DNA.
(a) (b) (c)
Figure 2: Moderately diﬀerentiated squamous cell carcinoma (hematoxylin and eosin) (a) lacking evidence of HPV infection by p16
immunohistochemical stain (b) or in situ hybridization (c). Though well and moderately-diﬀerentiated lesions tend to be negative for HPV,
and poorly-diﬀerentiated lesions are typically HPV positive, there is signiﬁcant morphologic overlap between HPV positive and negative
tumors.
protease digestion, denaturing temperatures below 95◦C,
andaninsuﬃcientnumberofcopiesofthetargetDNAinthe
cell[27–29].Approximately10to20copiesofthetargetDNA
percellarerequiredfordetectionbystandardISHtechniques
[28, 29].
Thesensitivityoftheassayisincreasedbysignalenhance-
ment techniques. One such technique is tyramide signal
ampliﬁcation, which has been shown to have a 10 to 100-
fold increase on sensitivity [28]. In this system, peroxidase-
conjugated streptavidin is applied to DNA-DNA hybridiza-
tion mixture, followed by incubation with biotinylated tyra-
mide. Peroxidase-conjugated streptavidin is then applied,
and lastly, the chromogenic substrate diaminobenzidine is
added [29]. Using an enzymatic ampliﬁcation procedure
such as this one allows a low copy number of a nucleic acid
sequenceto be identiﬁed. Such techniques have increased the
sensitivityofISHtotheextentthatitcandetectaslittleasone
to two copies of DNA per cell [4, 29].
Nevertheless,thesensitivityofISHappearstobelessthan
that seen in PCR analysis, as a metaanalysis by Termine et al.
found HPV in 39.9% of cases by PCR compared to 29.8% by
ISH[30].However,duetothenatureoftheprobeforspeciﬁc
viral nucleic acid sequences, ISH is highly speciﬁc for HPV
infection,markedlymoresothanp16immunohistochemical
staining [28]. Based on the diﬀerences in sensitivity and
speciﬁcity between tests, some authors have recommended
two-tiered systems of HPV detection, such as the use of
p16 immunohistochemistry as a screening tool and ISH as
a conﬁrmatory test [28, 31].
4. PolymeraseChainReactionDetectionofHPV
PCR is a process in which a signal sequence of DNA or
mRNA is ampliﬁed several orders of magnitude through
several rounds of denaturing at high temperature (∼95◦C),
annealing of complimentary oligonucleotide primers at a
lower temperature (∼55◦C), and DNA replication at an
intermediate temperature (∼72◦C) by a heat-resistant DNA
polymerase. In theory, it can be used to detect as few as
one copy of a DNA sequence, making it a highly sensitive
detection assay [4].
Material for PCR can be obtained from FFPE tissue by
scraping tissue from a tissue block, digesting, centrifuging,
and using the resultant supernatant for PCR studies [32]. In
addition, samples can be obtained for direct PCR analysis via
fresh tissue from oral biopsies [1]. In general, PCR for HPV4 Pathology Research International
is more sensitive on fresh frozen tissue compared to FFPE
tissue [27].
PCR has the advantages of being highly sensitive for
HPV detection, widely available, and cost eﬀective. However,
standard PCR techniques have a number of drawbacks.
PCR has lower speciﬁcity than ISH and is technically
cumbersome to perform [27]. In contrast to ISH, it does
not allow distinction between HPV that is present in the
neoplastic cells and HPV that is present in surrounding
nonneoplastic epithelium or stroma, nor can it distinguish
between episomal and integrated HPV DNA [4, 26, 27]. In
addition,whileprimerstargetingtheconservedL1regionare
commonlyemployed, thisregionmaybedeletedduring viral
integration, potentially reducing the sensitivity [27, 32, 33].
However, Agoston et al. found that PCR directed at L1 was
more sensitive than PCR directed at the obligate virulence
factor E7 (90.2% compared to 72.5%), suggesting that loss
of L1 is not seen in a signiﬁcant number of cases and thus
likely does not have a major inﬂuence on sensitivity of HPV
detection [33].
Several PCR ampliﬁcation techniques are commercially
available. These PCR screening assays commonly have
primers designed to amplify a region of DNA that is
present in multiple HPV types (most commonly within the
highly conserved L1 gene) [4, 33]. Since most commercially
available PCR kits use consensus sequences from multiple
HPV subtypes, speciﬁc typing is generally not possible
through PCR alone. Among the more commonly commer-
cially available primer sets are PGMY09/11, GP5+/GP6+,
and SPF10 LiPA [34]. All three target sequences within the
L1genethoughtheyareofvaryinglength(450basepairs,140
basepairs,and65basepairs,resp.).Targetingshorterstretches
of DNA generally results in higher sensitivity on FFPE tissue,
as DNA fragmentation often occurs during extraction from
the archived tissue [34]. Thus, the GP5+/GP6+ and SPF10
primers are more ideal for use in FFPE tissue from surgical
specimens. As noted previously, the Lewis et al. study found
HPV positivity by PCR in 86% of p16 positive SCC [24],
while the Thavaraj et al. study found HPV positivity by PCR
in 99% of p16 positive SCC [25]. The notable diﬀerence
between these studies was the use of SPF10 primers in
the former and GP5+/GP6+ in the latter. Diﬀerences in
sensitivities between the diﬀerent primer sets could explain
this discrepancy. However, to our knowledge, no study has
been done to directly compare the sensitivities of these two
primer sets in detecting HPV in oropharyngeal SCC.
The use of real-time PCR has also been assessed in
HPV detection. Real-time PCR allows for quantiﬁcation of
target DNA via colorimetric markers that accumulate during
PCRampliﬁcation,allowingamechanismofidentiﬁcationof
HPV DNA as well as an estimation of viral load [4, 23]. This
quantitative approach may allow for identiﬁcation of more
clinicallyrelevanthighviralloads,and,whentargetedagainst
mRNA, provides evidence of active gene transcription [27].
However, real-time PCR does not diﬀerentiate between
integrated and episomal DNA [23].
Recent studies have looked into the ability of PCR to
distinguishbetweenepisomalandintegratedHPVDNA.The
HPVgeneforE2proteinisacommonbreaksitepriortoviral
integrationintothehostgenome[4].E2proteinisaregulator
of E6 and E7 proteins, and its gene disruption results in
upregulation of these tumorigenic factors [35]. When E2 is
disrupted, PCR with primers designed to amplify the entire
E2 gene will fail [4]. Thus, comparing PCR ampliﬁcation of
the E2 gene with a gene known to rarely be disrupted during
integration (such as the E6 gene) can suggest whether the
viral DNA is integrated or not, as the ampliﬁcation ratio of
E2 to E6 would be lower in integrated HPV compared to
episomal HPV [4, 20, 36]. However, HPV DNA breakpoints
are known to be variable, so E2 disruption is not necessarily
seen in all integrated cases, limiting the sensitivity of this
technique [4, 37]. Further, it is known that intact episomal
E2 may be present even when integrated E2 is disrupted in
cases of SCC of the cervix, potentially further reducing the
sensitivity [38].
Finally, there are a number of commercially available
assays for the detection of HPV by PCR by reverse transcrip-
tase PCR. These kits target mRNA of the oncogenic E6 and
E7 proteins. Thus, they have the advantage of detecting tran-
scriptionally active HPV [4, 26]. It has the disadvantage
of being time consuming and technically diﬃcult. Further,
performance of reverse transcriptase PCR is generally better
on fresh tissue than FFPE tissue [4].
Overall, PCR is a reliable, sensitive marker of HPV DNA.
Nonetheless, ISH still has a number of advantages over PCR,
including higher speciﬁcity, the ability to reliably distinguish
episomal from integrated HPV DNA, and the ability to
localize HPV to the area of neoplasia.
5. Additional Techniques for HPV Detection
Over the past two decades, a technique has been developed
for combining PCR and ISH, referred to as PCR in situ
hybridization (PISH) [27, 39, 40]. In this case, PCR is
performed using typical PCR reagents performed on FFPE
tissue slides [27, 39]. The slide is then washed, dehydrated in
alcohol, and dried. The PCR products present on the slide
are then hybridized with speciﬁc DNA probes in the same
manner that standard ISH is performed [39]. PISH can be
utilized to perform PCR for HPV on intact tissue prepara-
tionsofSCCfollowedbyinsituhybridizationdetection,thus
combining the sensitivity of PCR with the tissue localization
of ISH [27, 39]. Studies looking at HPV detection rates in
cervical invasive and in situ SCC have found signiﬁcantly
higher detection rates with PISH compared to ISH alone
[39–42]. However, to date, no studies have looked at
the utility of PISH in detecting HPV in oropharyngeal
SCC.
Another hybridization technique, coined hybrid capture
II (HC-II) has been developed and utilized in the detection
of HPV. This is an FDA-approved method for HPV detection
in cervical pap smears, and studies have demonstrated its
utilityindemonstratingthepresenceofHPVinlesionsofthe
cervix and oropharynx [1, 26, 43, 44]. Suspicious lesions in
the oropharynx are sampled by brush [1]. DNA is extracted
from the exfoliated cells, denatured, and converted to single-
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HPV subtypes—typically as a cocktail of multiple high-risk
types—are then hybridized in solution [1]. These DNA-RNA
hybrids are put in microwell plates coated with anti-DNA-
RNA hybrid antibodies. The immobilized complex is then
reacted with antibodies conjugated to alkaline phosphatase,
and cleavage of an added chemiluminescent substrate is
measured by emitted light [1]. The intensity of the light
emitted allows for an estimation of the viral load. Chaudhary
et al. found increased sensitivity for HC-II compared to PCR
in the detection of HPV in oropharyngeal SCC [1]. This test
has the advantage of allowing HPV testing without the need
for biopsy. However, because the reaction occurs in solution,
it does not allow for localization of HPV to a histological
area of interest. In addition, the high-risk probe cocktail
typically used has been shown to detect at least 28 non-
targeted HPV types, including many low-risk HPV types,
creating the potential for false positives [26].
While IHC staining against p16 is frequently used as
a surrogate marker of HPV, to date, IHC staining against
speciﬁc HPV proteins has generally not been performed.
Nevertheless, the development of IHC stains against the
oncogenic E6 and E7 proteins would have a number of
potential advantages over other HPV detection methods. It
would have the ability to prove that HPV DNA is being
expressed and directly demonstrate that important HPV
oncogene proteins are present [4]. Development of reliable
antibodies against E6 and E7 protein could be an excellent
means for HPV detection in the future.
6. Conclusion
A number of tests for the detection of HPV in oropharyngeal
SCC are available, each possessing its own strengths and
weaknesses. At the present time, IHC staining for p16 and
PCR for HPV appear to be the most sensitive markers of
HPV, while ISH confers the greatest speciﬁcity. For most
clinical laboratories, the combination of a sensitive test (e.g.,
p16 IHC) and a speciﬁc test (e.g., ISH) allows for the best
potential to accurately establish the presence or absence of
HPV in a given case of SCC.
The study by Thavaraj et al. utilizes an algorithm origi-
nally developed by Weinberger et al. [25, 45]i nw h i c ho r o -
pharyngeal SCCs are classiﬁed ﬁrst by p16 status and then by
HPV status (either by PCR or ISH). In this way, SCCs are
categorizing as p16−/HPV− (Class I), p16−/HPV+ (Class
II), p16+/HPV+ (Class III), or p16+/HPV− (Class IV). Of
note, when PCR was used to assess HPV status, 9% of cases
fellintotheClassIIcategory(p16−/HPV+)comparedtojust
1% when ISH was used [25]. Given the fact that HPV PCR is
known to lack speciﬁcity relative to ISH (89% speciﬁcity in
the study by Smeets et al.), HPV positivity in the absence of
p16 positivity by IHC may represent false positivity [23, 25].
In contrast, when ISH was used to assess HPV status, 11% of
cases fell into the Class IV category (p16+/HPV−)c o m p a r e d
to just 2% by PCR. Since ISH is known to lack sensitivity
relativetoPCR(86%sensitivityinthestudybySmeetsetal.),
it is reasonable to assume that some of these Class IV cases
represent false negatives [23, 25].
Given the relative frequency of discordant p16 and HPV
results (i.e., Class II or Class IV) when using p16 in conjunc-
tion with a single HPV test, Thavaraj et al. suggest a three-
tiered algorithm. Tumors are still categorized as p16 positive
or negative by IHC. Those that are negative are then assessed
for HPV by ISH and ultimately categorized accordingly as
C l a s sI( p 1 6 −/HPV−) or Class II (p16−/HPV+). Likewise,
tumors that are p16 positive are initially assessed for HPV by
ISH, and if ISH is positive, the tumor is categorized as Class
III (p16+/HPV+). However, if the tumor is negative by ISH,
ac o n ﬁ r m a t o r yP C Rt e s ti sp e r f o r m e d .I ft h et u m o ri ss t i l l
negative by PCR, it is classiﬁed as Class IV (p16+/HPV−).
On the other hand, if the tumor is positive for HPV by PCR,
the tumor is considered Class III (p16+/HPV+) despite the
negative ISH result.
In their study, this three-tiered approach resulted in just
a small minority of cases falling under one of the discordant
categories(1%classII,1%classIV),withconcordanceofp16
and HPV results in 97% (35% class I, 62% class III). This
study suggests that with the three most commonly utilized
tests, HPV status can be conﬁdently determined in the vast
majority of cases of oropharyngeal SCC.
In the future, more recently applied molecular tech-
nologies, such as PISH and HC-II, may oﬀer even more
accurate diagnosis of HPV in the clinical laboratory, and
development of IHC against important viral proteins may
ultimately provide the optimal test for active HPV genomic
transcription and translation in SCC. Nonetheless, using
current ancillary tests in combination with clinical clues and
morphology, such as the presence of nonkeratinizing, poorly
diﬀerentiated lesions, HPV status can be accurately assessed
in the vast majority of cases of oropharyngeal SCC.
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